Auger electron emitting radionuclides have potential for the therapy of small-size cancers because of their high level of cytotoxicity, low-energy, high linear energy transfer, and short range biologic effectiveness. Auger emitter 165Er (T1/2 = 10.3 h, IEC = 100%) is a potent nuclide for targeted radionuclide therapy. 165Er excitation function via 165Ho(p,n)165Er, 165Ho(d,2n)165Er, 166Er(p,2n)165Tm→165Er, 166Er(d,3n)165Tm→165Er, natEr(p,xn)165Tm→165Er and 164Er(d,n)165Tm→165Er reactions were calculated by ALICE/91, ALICE/ASH (GDH Model & Hybrid Model) and TALYS-1.2 (Equilibrium & Pre-Equilibrium) codes and compared to existing data. Requisite for optimal thicknesses of targets were obtained by SRIM code for each reaction.
No takes yet. Share an insight, caveat, or question.
Sadeghi et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: